Pfizer Inc (PFE)

36.56
0.29 0.79
NYSE : Health Care
Prev Close 36.85
Open 36.88
Day Low/High 36.50 / 36.91
52 Wk Low/High 28.25 / 37.19
Volume 16.25M
Avg Volume 24.75M
Exchange NYSE
Shares Outstanding 6.06B
Market Cap 223.37B
EPS 1.10
P/E Ratio 15.94
Div & Yield 1.20 (3.30%)

Latest News

Pfizer (PFE) Stock Down, Partners with Western Oncolytics on Cancer Technology

Pfizer (PFE) Stock Down, Partners with Western Oncolytics on Cancer Technology

Pfizer (PFE) will partner with Western Oncolytics to work on its oncolytic virus technology.

Earnings Post-Mortems and Previews

We check in on eight companies that already have reported results and three others that will report in the next couple weeks.

Jim Cramer: Second-Quarter Earnings Have Been Mixed

Jim Cramer: Second-Quarter Earnings Have Been Mixed

Even with half of S&P 500 companies having reported, a clear picture of the earnings season remains murky.

3 Stocks Pushing The Health Care Sector Downward

3 Stocks Pushing The Health Care Sector Downward

TheStreet highlights 3 stocks pushing the health care sector lower today.

Allergan Cures Its Ailing Chart

Allergan Cures Its Ailing Chart

The stock has broken free of tiresome resistance in a big way.

Pfizer And Western Oncolytics Announce Immuno-Oncology Research Collaboration To Investigate Novel Oncolytic Virus Technology

Pfizer And Western Oncolytics Announce Immuno-Oncology Research Collaboration To Investigate Novel Oncolytic Virus Technology

Pfizer Inc. (NYSE:PFE) and Western Oncolytics announced today that they have entered into a development collaboration, license and option agreement to advance Western Oncolytics' novel oncolytic vaccinia virus, WO-12.

Chart of the Day: Allergan

The stock has broken free of tiresome resistance in a big way.

Experimental Tau Protein Drug Tangled Up in Late-Stage Alzheimer's Study Failure

Experimental Tau Protein Drug Tangled Up in Late-Stage Alzheimer's Study Failure

A TauRx Therapeutics drug designed to dissolve tangles of a protein called tau in the brain failed to slow cognitive and functional declines of Alzheimer's patients compared with a control.

Biogen Should Either a Buyer or a Seller Be

Biogen Should Either a Buyer or a Seller Be

The company sans CEO Scangos needs to do some type of deal in the coming months.

Will Pfizer Book Another Healthy Quarter?

Will Pfizer Book Another Healthy Quarter?

Pfizer shares are up 13% year to date, and the company reports earnings on Aug. 2. Here's what to expect.

Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal

Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal

Investors may want to look at some small-cap pharma names that could be takeover targets like Relypsa.

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.

Pfizer Receives World Health Organization Prequalification For Multi-Dose Vial Presentation Of Prevenar 13®

Pfizer Receives World Health Organization Prequalification For Multi-Dose Vial Presentation Of Prevenar 13®

Pfizer Inc. (NYSE: PFE) announced today that the World Health Organization (WHO) has prequalified its four-dose, multi-dose vial (MDV) presentation of Prevenar 13 ®* (pneumococcal polysaccharide conjugate vaccine [13 -...

Cramer: These Stocks Are the Key to the Bull Market

Cramer: These Stocks Are the Key to the Bull Market

Let me give you the unassailable themes.

Earnings Season Preview

We're checking out eight companies in the portfolio that are expected to report results over the next two weeks.

Shire Could Divest ADHD Treatment, Other Assets, for More Upside Post-Baxalta

Shire Could Divest ADHD Treatment, Other Assets, for More Upside Post-Baxalta

At least one company follower believes the divestiture of Shire's Neurology division for as much as $13 billion would be a logical next move.

3 Stocks Advancing The Health Care Sector

3 Stocks Advancing The Health Care Sector

TheStreet highlights 3 stocks pushing the health care sector higher today.

The GOP's Tax Plan Is Great for Corporate America

The GOP's Tax Plan Is Great for Corporate America

The House Republicans' tax reform plan is a pretty good deal according to one analysis, especially for American corporations.

Glaxo Gains Jefferies Upgrade on Stronger HIV Drugs Performance, Currency Benefits

Glaxo Gains Jefferies Upgrade on Stronger HIV Drugs Performance, Currency Benefits

Shares in the U.K.'s leading pharmaceuticals company have risen about 20% since the June 23 Brexit vote.

Theresa May to Be Appointed New U.K. Prime Minister

Theresa May to Be Appointed New U.K. Prime Minister

Corporate governance changes are among the policy flagships unveiled by the successor to David Cameron.

Pfizer Announces The Publication Of Final Results From Two Pivotal Phase 3 Studies Of Crisaborole Topical Ointment In Patients With Mild To Moderate Atopic Dermatitis

Pfizer Announces The Publication Of Final Results From Two Pivotal Phase 3 Studies Of Crisaborole Topical Ointment In Patients With Mild To Moderate Atopic Dermatitis

Pfizer Inc. (NYSE:PFE) announced today the publication of findings from two pivotal Phase 3 studies of investigational crisaborole topical ointment 2% (formerly AN2728) in the online issue of the Journal of the American...

Will Pfizer (PFE) Stock Be Affected by Pneumonia Vaccine Approval?

Will Pfizer (PFE) Stock Be Affected by Pneumonia Vaccine Approval?

The FDA approved Pfizer’s (PFE) pneumonia vaccine for infants and younger adults.

Pfizer Receives FDA Approval For Prevnar 13® In Adults Age 18 Through 49

Pfizer Receives FDA Approval For Prevnar 13® In Adults Age 18 Through 49

Pfizer Inc. (NYSE:PFE) today announced that Prevnar 13 ® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) received U.

Cramer: 10 Stocks That Need to Start Doing Better

Cramer: 10 Stocks That Need to Start Doing Better

They need to do something that makes them stand out as stocks you want to own, not avoid.

Pfizer Announces Positive Top-Line Results From Phase 3 S-TRAC Trial Of SUTENT® (sunitinib) As Adjuvant Therapy In Patients At High Risk Of Recurrent Renal Cell Carcinoma

Pfizer Announces Positive Top-Line Results From Phase 3 S-TRAC Trial Of SUTENT® (sunitinib) As Adjuvant Therapy In Patients At High Risk Of Recurrent Renal Cell Carcinoma

Pfizer Inc. (NYSE:PFE) today announced that the S-TRAC clinical trial ( Sunitinib Trial in Adjuvant Renal Cancer), a Phase 3 study of SUTENT versus placebo in the adjuvant setting, met its primary endpoint of...

Jim Cramer's 'Mad Money' Recap: Why You Need Technical Analysis

Jim Cramer's 'Mad Money' Recap: Why You Need Technical Analysis

Why study charts? Because charts are like the footprints at the scene of the crime, clues to what the big money managers are likely thinking, Cramer says.

Medivation Tries to Prove Its Worth

Medivation Tries to Prove Its Worth

A call with investors Wednesday highlights drugs in the pipeline that could be attractive to bidders that reportedly include Sanofi, Pfizer and Celgene, among others.